96 results
Search Results
2. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.
3. Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis.
4. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.
5. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.
6. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply.
7. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do?
8. Editorial: in the era of effective antiviral therapy, long‐term dynamic endoscopic monitoring does not seem to be necessary for all CHB patients with compensated cirrhosis.
9. Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors' reply.
10. Letter: should we abandon FIB‐4 to characterise noninvasively patients with NAFLD? Authors' reply.
11. Letter: should we abandon FIB‐4 to characterise non‐invasively patients with NAFLD?
12. Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding—the plot thickens!
13. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply.
14. Letter: opioid usage is associated with rectal hyposensitivity in patients with opioid‐induced constipation.
15. Editorial: terlipressin in patients with ACLF grade 3—too late? Authorsʼ reply.
16. Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era? Authors' reply.
17. Editorial: symptoms predicting active intestinal inflammation in patients with IBD.
18. Editorial: terlipressin in patients with acute‐on‐chronic liver failure grade 3—too late?
19. Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply.
20. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
21. Editorial: Percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites—Is it safe?
22. Letter: the duration of a patient's long‐term stability on anti‐TNFs should be considered before nonmedical switching to a biosimilar.
23. Editorial: hepatitis C virus (HCV) disease progression - HCV cure and the elimination of the 'ethnic slope'.
24. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply.
25. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF therapy.
26. Letter: immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era.
27. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet? Authors' reply.
28. Editorial: risk of loss of response to anti‐TNFα agents in patients with inflammatory bowel disease—the longer the less?
29. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet?
30. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring.
31. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors' reply.
32. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately.
33. Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites ‐ is it safe? Authors' reply.
34. Editorial: 5‐ASA in IBD patients on biologics—'stop or continue'?
35. Editorial: topiramate for cyclic vomiting syndrome—for refractory patients only?
36. Editorial: outcomes following a second switch—evaluating clinical outcomes and patient perspectives in IBD.
37. Letter: SARS‐CoV‐2 infection in two IBD patients treated with dual targeted therapy.
38. Letter: TIPSS improves muscle mass indices in patients with cirrhosis and severe portal hypertension – authors' reply.
39. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring. Authors' reply.
40. Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply.
41. Editorial: treating the liver to treat the kidney in non-alcoholic steatohepatitis.
42. Letter: ACE2, IBD and COVID‐19—why IBD patients may be at reduced risk of COVID‐19.
43. Letter: liver involvement and mortality in COVID‐19 patients – authors' reply.
44. Editorial: outcome prediction in patients with cirrhosis and acute‐on‐chronic liver failure—authors' reply.
45. Letter: does early transjugular intrahepatic porto‐systemic shunt really have no effect on survival in high‐risk patients with oesophageal variceal bleeding?
46. Editorial: current challenges in predicting mortality in patients with cirrhosis and refractory ascites.
47. Letter: immunotherapy for IBD patients in a SARS‐CoV‐2 endemic area—authors' reply.
48. Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID‐19.
49. Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area.
50. Editorial: which factors influence HBsAg levels in HBV‐infected patients? Authors' reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.